The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikiforova T.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Shchekochikhin D.Iu.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova;
Moskovskiĭ gosudarstvennyĭ universitet im. M.V. Lomonosova

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Syrkin A.L.

Sechenov First Moscow State Medical University

Prognostic value of biomarkers in chronic heart failure with preserved left ventricular ejection fraction

Authors:

Nikiforova T.A., Shchekochikhin D.Iu., Kopylov F.Iu., Syrkin A.L.

More about the authors

Journal: Therapeutic Archive. 2016;88(9): 102‑105

DOI: 10.17116/terarkh2016889102-105

Read: 2891 times

Download PDF (RU)
Contact the author
Table of contents

PROGNOSTIC VALUE OF BIOMARKERS IN CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
PROGNOSTIC VALUE OF BIOMARKERS IN CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION

To cite this article:

Nikiforova TA, Shchekochikhin DIu, Kopylov FIu, Syrkin AL. Prognostic value of biomarkers in chronic heart failure with preserved left ventricular ejection fraction. Therapeutic Archive. 2016;88(9):102‑105. (In Russ.)
https://doi.org/10.17116/terarkh2016889102-105

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The paper reviews major biomarkers for determining the prognosis in patients with chronic heart failure and preserved ejection fraction. It also considers cystatin C, one of the novel and probably the most practically important biomarkers.

Keywords:

chronic heart failure with preserved ejection fraction; natriuretic peptide; galectin-3; urodilatin; C-type natriuretic peptide (CNP); D-type natriuretic peptide; cystatin C; growth- stimulating factor (ST2)

Authors:

Nikiforova T.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Shchekochikhin D.Iu.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova;
Moskovskiĭ gosudarstvennyĭ universitet im. M.V. Lomonosova

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Syrkin A.L.

Sechenov First Moscow State Medical University

Close metadata

References:

  1. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587. doi:10.1001/jama.290.19.2581
  2. Brouwers FP, de Boer RA et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424-1431. doi:10.1093/eurheartj/eht066 
  3. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med. 2006;355(3):251-259.  doi:10.1056/nejmoa052256 
  4. Mareev V, Danielyan M, Belenkov Y. Comparative characteristics of heart failure patients depended on ejection fraction from Russian multicenter study EPOHA-O-HSN. Serdechnaya nedostatochnost′. 2006;7(4):164-171. (In Russ.)
  5. Shcherbinina E, Bazhin Y, Vaysberg A et al. 9-years dynamics of heart failure etiology in representative population of Nizhegorodskaya oblast (1998-2007). Serdechnaya nedostatochnost: vserossiyskaya konferenciya OSSN. Moscow; 2007. (In Russ.)
  6. Dikur O, Poltavskaya M, Giverts I et al. Ventricular-arterial coupling in case of chronic heart failure with preserved and reduced left ventricular ejection fraction. Kardiologiya i serdechno-sosudistaya chirurgiya. 2014;4:59-68. (In Russ.)
  7. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J. 2008;155(2):200-207.  doi:10.1016/j.ahj.2006.10.043
  8. Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832 (12):2442-2450. doi:10.1016/j.bbadis.2012.12.014
  9. Cea LB. Natriuretic peptide family: new aspects. Cur Med Chem-Cardiovasc Hematol Agents. 2005;3(2):87-98.  doi:0.2174/1568016053544309 
  10. Shchekochikhin D, Kopylov Ph, Kozlovskaya N, Syrkin A. Cardiorenal syndrome in decompensated heart failure. Serdechnaya nedostatochnost′. 2012;4:248-252. (In Russ.)
  11. Iqbal N, Alim KS, Aramin H et al. Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther. 2013;11(9):1155-1169. doi:10.1586/14779072.2013.832476 
  12. Maisel A, Mueller C, Nowak R et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-2076. doi:10.1016/j.jacc.2010.02.025 
  13. Anker DS, Auriccnio A, Bohm M et al. ESC Cuidelines for diagnosisand treatmentof acute and chronic heart failure. Eur Heart J. 2012;33(14):1787-1847. doi:10.1093/eurheartj/ehs104 
  14. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol - Renal Physiol. 2003;284(5):F1115-F1119. doi:10.1152/ajprenal.00337.2002
  15. van Veldhuisen DJ, Linssen GCM, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498-1506. doi:10.1016/j.jacc.2012.12.044 
  16. Bongartz LG, Braam B, Verhaar MC et al. The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction. AJP: Heart Circul Physiol. 2010;299(6):H2037-H2045. doi:10.1152/ajpheart.00400.2010 
  17. Kociol RD, Pang PS, Gheorghiade M et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-1078. doi:10.1016/j.jacc.2010.06.016 
  18. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalaized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies and outcomes. Circulaition. 2012;126(1):65-75.  doi:10.1161/circulationaha.111.080770
  19. Solomakhina N. Systolic and diastolic heart failure: characteristics of clinic and myocardial injury, prognosis. [dissertation]. Moscow; 2011. Available at: http://medical-diss.com/docreader/349870/d?#?page=1 (In Russ.)
  20. Sharma UC. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-3128. doi:10.1161/01.cir.0000147181.65298.4d 
  21. Edelmann F, Holzendorf V, Wachter R et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2014;17(2):214-223.  doi:10.1002/ejhf.203 
  22. Jaarsma T, van Veldhuisen DJ. When, how and where should we «coach» patients with heart failure: the COACH results in perspective. Eur J Heart Fail. 2008;10(4):331-333.  doi:10.1016/j.ejheart.2008.02.017 
  23. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCEF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):240-327.  doi:10.1161/cir.0b013e31829e8776
  24. Shimpo M et al. Serum levels of the interleukin‑1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-2190. doi:10.1161/01.cir.0000127958.21003.5a
  25. Manzano-Fernandez S, Mueller T, Pascual-Figal D et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259-267.  doi:10.1016/j.amjcard.2010.09.011
  26. Schmidt-Ott KM et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Cur Opini Nephrol Hypertens. 2006;15(4):442-449.  doi:10.1097/01.mnh.0000232886.81142.58 
  27. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987-1996. doi:10.1016/j.jacc.2005.11.084 
  28. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705-2712. doi:10.1093/eurheartj/ehr190
  29. Ichimura T. Kidney injury molecule-1 (KIM-1), a putativeepithelial cell adhesion molecule containing a novel immunoglobulindomain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-4142. doi:10.1074/jbc.273.7.4135
  30. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-b-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011;13(10):1104-1110. doi:10.1093/eurjhf/hfr102
  31. Medical laboratory technology: Guidance for clinical laboratory diagnostics in 2 volumes. 3rd edition, revised and enlarged. Ed. by Karpishchenko A. Moscow: GEOTAR-Media; 2013. (In Russ.)
  32. Villevalde S, Gudgalis N, Isikova H et al. Cystatin C as an indicator of functional cross-talk between kidney and inflammation in patients with arterial hypertension and diabetes mellitus type 2. Klinicheskaya farmakologiya i terapiya. 2009;1:21-25. (In Russ.)
  33. Croda-Todd MT, Soto-Montano XJ, Hernández-Cancino PA, Juárez- Aguilar E. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin Biochem. 2007;40(13-14):1084-1077. doi:10.1016/j.clinbiochem.2007.05.011 
  34. Sarnak MJ. Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults. Ann Int Med. 2005;142(7):497-505.  doi:10.7326/0003-4819-142-7-200504050-00008
  35. Tang WHW, van Lente F, Shrestha K et al. Impact of Myocardial Function on Cystatin C Measurements in Chronic Systolic Heart Failure. J Card Fail. 2008;14(5):394-399.  doi:10.1016/j.cardfail.2008.01.006
  36. Stewart GA, Gansevoort RT, Mark PB et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67(1):217-226.  doi:10.1111/j.1523-1755.2005.00072.x
  37. Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, Martínez-Marcos FJ, Camacho-Vázquez C, Ruiz-Frutos C, Pujol-De La Llave E. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail. 2011;17(1):31-38.  doi:10.1016/j.cardfail.2010.07.248
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.